ID   HSC-39
AC   CVCL_A385
SY   HSC39
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 891
DR   cancercelllines; CVCL_A385
DR   Cell_Model_Passport; SIDM00045
DR   CGH-DB; 106-1
DR   CGH-DB; 9001-4
DR   Cosmic; 875904
DR   Cosmic; 876557
DR   Cosmic; 877037
DR   Cosmic; 897522
DR   Cosmic; 922691
DR   Cosmic; 926116
DR   Cosmic; 1223584
DR   Cosmic; 1460703
DR   Cosmic; 1518248
DR   Cosmic; 1571763
DR   Cosmic-CLP; 1322224
DR   DepMap; ACH-002141
DR   EGA; EGAS00001000978
DR   GDSC; 1322224
DR   GEO; GSM1669905
DR   IARC_TP53; 13724
DR   JCRB; JCRB1864
DR   PharmacoDB; HSC39_621_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54896389
RX   PubMed=1846312;
RX   PubMed=11107048;
RX   PubMed=11543663;
RX   PubMed=15723654;
RX   PubMed=26934957;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 28-30 hours (PubMed=1846312).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Homozygous (PubMed=11107048; Cosmic-CLP=1322224; DepMap=ACH-002141).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.43%; Native American=0%; East Asian, North=78.69%; East Asian, South=18.67%; South Asian=0.72%; European, North=1.03%; European, South=0.47% (PubMed=30894373).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): Cosmic-CLP=1322224; JCRB=JCRB1864
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 9
ST   D16S539: 9
ST   D5S818: 13 (Cosmic-CLP=1322224)
ST   D5S818: 13,14 (JCRB=JCRB1864)
ST   D7S820: 11,12 (JCRB=JCRB1864)
ST   D7S820: 12 (Cosmic-CLP=1322224)
ST   TH01: 7,9
ST   TPOX: 8
ST   vWA: 14
DI   NCIt; C5250; Gastric signet ring cell adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A386 ! HSC-40A
SX   Male
AG   54Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 02-05-24; Version: 29
//
RX   PubMed=1846312;
RA   Yanagihara K., Seyama T., Tsumuraya M., Kamada N., Yokoro K.;
RT   "Establishment and characterization of human signet ring cell gastric
RT   carcinoma cell lines with amplification of the c-myc oncogene.";
RL   Cancer Res. 51:381-386(1991).
//
RX   PubMed=11107048; DOI=10.1046/j.1440-1827.2000.01117.x;
RA   Yokozaki H.;
RT   "Molecular characteristics of eight gastric cancer cell lines
RT   established in Japan.";
RL   Pathol. Int. 50:767-777(2000).
//
RX   PubMed=11543663; DOI=10.1006/viro.2001.1071;
RA   Fukuda M., Ikuta K., Yanagihara K., Tajima M., Kuratsune H.,
RA   Kurata T., Sairenji T.;
RT   "Effect of transforming growth factor-beta1 on the cell growth and
RT   Epstein-Barr virus reactivation in EBV-infected epithelial cell
RT   lines.";
RL   Virology 288:109-118(2001).
//
RX   PubMed=15723654; DOI=10.1111/j.1349-7006.2005.00016.x; PMCID=PMC11160020;
RA   Takada H., Imoto I., Tsuda H., Sonoda I., Ichikura T., Mochizuki H.,
RA   Okanoue T., Inazawa J.;
RT   "Screening of DNA copy-number aberrations in gastric cancer cell lines
RT   by array-based comparative genomic hybridization.";
RL   Cancer Sci. 96:100-110(2005).
//
RX   PubMed=26934957; DOI=10.1038/srep22371; PMCID=PMC4776110;
RA   Kurashige J., Hasegawa T., Niida A., Sugimachi K., Deng N., Mima K.,
RA   Uchi R., Sawada G., Takahashi Y., Eguchi H., Inomata M., Kitano S.,
RA   Fukagawa T., Sasako M., Sasaki H., Sasaki S., Mori M., Yanagihara K.,
RA   Baba H., Miyano S., Tan P., Mimori K.;
RT   "Integrated molecular profiling of human gastric cancer identifies
RT   DDR2 as a potential regulator of peritoneal dissemination.";
RL   Sci. Rep. 6:22371-22371(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//